Abstract：
UNASSIGNED: Despite several therapeutic advancements, the proportion of patients with advanced biliary tract cancers (BTC) surviving 5 years from diagnosis remains dismal. The increasing recognition of targetable genetic alterations in BTCs has ushered in a new era in the treatment of these patients. Newer therapeutic agents targeting mutations such as isocitrate dehydrogenase (IDH), fibroblastic growth factor receptor (FGFR), human epidermal growth factor receptor (HER), and so on have established a new standard of care for treatment upon progression on frontline therapy in patients with disease harboring these mutations.
UNASSIGNED: The current review aims to concisely summarize progress with various targeted therapy options for BTC. We also briefly discuss future directions in clinical and translational research for the adoption of a personalized approach for the treatment of unresectable or advanced BTC.
UNASSIGNED: Several new agents continue to emerge as feasible treatment options for patients with advanced BTC harboring targetable mutations. There is a growing need to identify mechanisms to conquer primary and acquired resistance to these agents. The identification of potential biomarkers that predict response to targeted therapy may be helpful in adopting a more tailored approach. All patients receiving treatment for advanced BTC should undergo tissue genomic profiling at diagnosis.
UNASSIGNED: The current review aims to concisely summarize progress with various targeted therapy options for BTC. We also briefly discuss future directions in clinical and translational research for the adoption of a personalized approach for the treatment of unresectable or advanced BTC.
UNASSIGNED: Several new agents continue to emerge as feasible treatment options for patients with advanced BTC harboring targetable mutations. There is a growing need to identify mechanisms to conquer primary and acquired resistance to these agents. The identification of potential biomarkers that predict response to targeted therapy may be helpful in adopting a more tailored approach. All patients receiving treatment for advanced BTC should undergo tissue genomic profiling at diagnosis.
摘要：
■尽管在治疗方面取得了一些进展，晚期胆道癌(BTC)患者在确诊后存活5年的比例仍然很低.对BTC中可靶向遗传改变的日益认识开启了治疗这些患者的新纪元。新的治疗剂靶向突变，如异柠檬酸脱氢酶（IDH），成纤维细胞生长因子受体（FGFR），人表皮生长因子受体(HER),等。在有这些突变的疾病患者的一线治疗进展时，已经建立了新的治疗标准。
■本综述旨在简要总结BTC各种靶向治疗方案的进展。我们还简要讨论了临床和转化研究的未来方向，以采用个性化方法治疗不可切除或晚期BTC。
一些新的药物继续出现，作为具有靶向突变的晚期BTC患者的可行治疗选择。越来越需要确定克服对这些试剂的原发性和获得性抗性的机制。识别预测对靶向治疗的反应的潜在生物标志物可能有助于采用更量身定制的方法。所有接受晚期BTC治疗的患者应在诊断时进行组织基因组分析。
■本综述旨在简要总结BTC各种靶向治疗方案的进展。我们还简要讨论了临床和转化研究的未来方向，以采用个性化方法治疗不可切除或晚期BTC。
一些新的药物继续出现，作为具有靶向突变的晚期BTC患者的可行治疗选择。越来越需要确定克服对这些试剂的原发性和获得性抗性的机制。识别预测对靶向治疗的反应的潜在生物标志物可能有助于采用更量身定制的方法。所有接受晚期BTC治疗的患者应在诊断时进行组织基因组分析。
